Top

Discover Oncology

Published in:

Open Access 01-12-2023 | Rectal Cancer | Research

Is serum thymidine kinase 1 a prognostic biomarker in primary tumor location of colorectal carcinomas?

Authors: Yujing Fang, Sven Skog, Qingjian Ou, Zhiheng Chen, Senbo Liu, Ailian Hei, Jin Li, Ji Zhou, Ellen He, Desen Wan

Published in: Discover Oncology | Issue 1/2023

Abstract

Aim

To assess whether serum thymidine kinase 1 (STK1p), CEA and CA19.9 can be used as prognostic biomarkers in the primary tumor location (PTL) of colorectal carcinoma (CRC). Additional clinical factors of TNM stage, pathological grade, age and sex were also included.

Methods

STK1p was determined by an ECL-dot-blot assay, and CEA/CA19.9 was determined by an automatic electrochemiluminescence analyzer in a retrospective presurgery of right-colon carcinoma (R-CC, n = 90), left-colon carcinoma (L-CC, n = 128) and rectal carcinoma (RC, n = 270). Prognostic factors were evaluated by COX and overall survival (OS).

Results

The multivariate-COX and OS in relation to the prognostic factors of PTL in CRC were different and complex. An elevated STK1p value was significantly associated with poor OS in RC (P = 0.002) and L-CC (P = 0.037) but not in R-CC (P > 0.05). Elevated CEA (P≈.000) and CA19.9 (P≈.000) were significantly associated with poor OS in RC but not in L-CC and R-CC. Multivariate-COX showed that STK1p (P = 0.02, HR = 1.779, 95%CI 1.30–7.582), CEA (P = 0.001, HR = 2.052, 95%CI 1.320–3.189), CA19.9 (P≈.000, HR = 2.574, 95%CI 1.592–4.162) and TNM-stage (P≈.000, HR = 2.368, 95%CI 1.518–3.694) were independent prognostic factors in RC, while TNM-stage was an independent prognostic factor only in R-CC (P = 0.011, HR = 3.139, 95% CI 1.30–7.582) and L-CC (P≈.000, HR = 4.168, 95%CI 1.980–8.852). Moreover, elevated STK1p was significantly more sensitive (P < .001) for predicting mortality than CEA and CA19.9. No correlation was found between STK1p, CEA or AFP.

Conclusion

Combining TNM stage and suitable biomarkers, STK1p provides further reliable information on the survival of PTL of CRC.

Caini S, Chioccioli S, Pastore E, Fontana M, Tortora K, Caderni G, Masala G. Fish consump etion and colorectal Cancer risk: meta-analysis of prospective epidemiological studies and review of evidence from animal studies. Cancers. 2022;14(3):640. https://doi.org/10.3390/cancers14030640.CrossRefPubMedPubMedCentral

Sawicki T, Ruszkowska A, Danielewicz E, Niedzwiedzka T, Arlukowicz T, Przybylowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancer. 2021;13(9):2025. https://doi.org/10.3390/cancers13092025.CrossRef

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yan F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. China Med J. 2022;135(5):584–90. https://doi.org/10.1097/CM9.0000000000002108.CrossRef

Martins ves BA, de Bulhões GF, Cavalcanti IN, Martins MM, de Oliveira PG, Martins AMA. Biomarkers in colorectal cancer: the role of translational proteomics research. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.01284.CrossRef

McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–57. https://doi.org/10.2174/0929867324666170111152436.CrossRefPubMed

Lauby-Secretan B, Vilahur N, Bianchini F, Guha N, Straif K. International agency for research on cancer handbook working group the IARC perspective on colorectal cancer screening. N Engl J Med. 2018. https://doi.org/10.1056/NEJMc1807173.CrossRefPubMedPubMedCentral

Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, Holm T, Harris CC, Link KH, Kornmann M. Are colon and rectal cancer two different tumor entities? A Proposal to abandon the term colorectal cancer. Int J Mol Sci. 2018;19(9):2577. https://doi.org/10.3390/ijms19092577.CrossRefPubMedPubMedCentral

Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, Kitagawa Y. Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution. Surg Today. 2014;44(9):1685–91. https://doi.org/10.1007/s00595-013-0748-5.CrossRefPubMed

Suttie SA, Shaikh I, Mullen R, Amin AI, Daniel T, Yalamarthi S. Outcome of right and left sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13(8):884–9. https://doi.org/10.1111/j.1463-1318.2010.02356.x.CrossRefPubMed

10.

Bustamante-Lopez LA, Nahas SC, Nahas CSR, Pinto RA, Marques CFS, Cecconello I. Is there a difference between right-versus left–sided colon cancer? Does side make any difference in long-time follow-up? Arq Bras Cir Dig. 2019;32(4):1479. https://doi.org/10.1590/0102-672020190001e1479.CrossRef

11.

Nagai Y, Kiyomatsu T, Gohda Y, Otani K, Deguchi K, Yamada K. The primary tumor location in colorectal cancer: a focused review on its impact on surgical management. Glob Health Med. 2021;3(6):386–93. https://doi.org/10.3577/ghm.2020.01096.CrossRefPubMedPubMedCentral

12.

Biju K, Zhang GQ, Stem M, Sahyoun R, Safar B, Atallah C, Efron JE, Rajput A. Impact of treatment coordination on overall survival in rectal cancer. Clin Colorectal Cancer. 2021;20(3):187–96. https://doi.org/10.1016/j.clcc.2021.01.002.CrossRefPubMedPubMedCentral

13.

Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of serum CEA, CA19–9, CA72–4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep. 2018;8(1):2732. https://doi.org/10.1038/s41598-018-21048-y.CrossRefPubMedPubMedCentral

14.

Ding Y, Xuan W, Chen C, Chen Z, Yang Z, Zuo Y, Ren S. Differences in carcinoembryonic antigen levels between colon and rectal cancer. Mol Clin Oncol. 2014;2(4):618–22. https://doi.org/10.3892/mco.2014.286.CrossRefPubMedPubMedCentral

15.

Wang Y, Jiang X, Wang S, Yu H, Zhang T, Xu S, Li W, He E, Skog S. Serological TK1 predict pre-cancer in routine health screenings of 56,178 people. Cancer Biomark. 2018;22(2):237–47. https://doi.org/10.3233/CBM-170846. (PMID: 29689706).CrossRefPubMed

16.

Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A, Schwentner C. Thymidine kinase and cancer monitoring. Cancer Lett. 2012;316(1):6–10. https://doi.org/10.1016/j.canlet.2011.10.025.CrossRefPubMed

17.

Skog S, He E, Haghdoost S. Prevention and Early Detection of Human Tumour. In: Skog S, editor. Lambert Academic Publishing. Berlin: Schaltungsdienst Lange OHG; 2017.

18.

Tribukait B. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume. BMC Cancer. 2020;20(1):440. https://doi.org/10.1186/s12885-020-06925. (PMID: 32423477).CrossRefPubMedPubMedCentral

19.

Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors. 2011;11(12):11064–80. https://doi.org/10.3390/s111211064.CrossRefPubMedPubMedCentral

20.

He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, Skog S. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 2006;26(6C):4753–9 (PMID: 17214336).PubMed

21.

Chen F, Tang L, Xia T, He E, Hu G, Li Y, et al. Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer. Mol Clin Oncol. 2013;1(5):894–902. https://doi.org/10.3892/mco.2013.149.CrossRefPubMedPubMedCentral

22.

Pan Z, Ji X, Shi Y, Zhou J, He E, Skog S. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J Cancer Res Clin Oncol. 2010;136(8):1193–9. https://doi.org/10.1007/s00432-010-0769-z.CrossRefPubMed

23.

Wang ZX, Zhang GQ, Li Z, Li J, Ma HB, Hei AL, Jiao S, Hu Y, Sun S, Wu L, Zhou J, Wang Y, He E, Skog S. SHTK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data. Future Sci OA. 2020. https://doi.org/10.2144/fsoa-2020-0130.CrossRefPubMedPubMedCentral

24.

Xu W, Cao X, Miao KR, Qiao C, Wu YJ, Liu Q, Fan L, Li JY. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol. 2009;90(2):205–11. https://doi.org/10.1007/s12185-009-0380-8.CrossRefPubMed

25.

Wang Y, Jiang X, Dong S, Shen J, Yu H, Zhou J, Ma H, He E, Sko S. Serum TK1 is a more reliable marker than CEA and AFP for cancer screening survey in a study of 56,286 people. Cancer Biomark. 2016;16(4):529–36. https://doi.org/10.3233/CBM-160594.CrossRefPubMed

26.

Chen ZH, Wang Y, Chen G, Cao X, Jiang XR, Ma HB, Zhou J, He E, Skog S. Chapter 21 Serum-Biomarker Thymidine Kinase 1 for Early Discovery of Tumour Process of 160086 Participants Using a Sensitive Immune ECL Dot-Blot Detection System. In: Yurish SY, editor. Advances in Sensors. Barcelona: Reviews International Frequency Sensor Association Publishing; 2018.

27.

Dang L, Ma H, Hei A, Xu S, Zhou J, He E, Skog S. A meta-analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment. Mol Clin Oncol. 2020;12(5):440–50. https://doi.org/10.3892/mco.2020.2002.CrossRefPubMedPubMedCentral

28.

Hei AL, Li J, Zhou J, He E, Skog S. IgY-polyclonal antibodies raised against C-terminal 31-peptide of human thymidine kinase 1 for detection of risk assessment in pre-carcinoma to carcinoma colorectal progression: a meta-analysis and systematic review. Ann Case Report. 2022. https://doi.org/10.2901/2574-7754.100803.CrossRef

29.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK), statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Br J Cancer. 2005;93(4):387–91. https://doi.org/10.1038/sj.bjc.6602678.CrossRefPubMedPubMedCentral

30.

Singh S, Kumar R, Kumar U, Kumari R. Clinical significance and role of TK1, CEA, CA 19–9 and CA 72–4 levels in diagnosis of colorectal cancers. Asian Pac J Cancer Prev. 2020;21(11):3133–6. https://doi.org/10.31557/APJCP.2020.21.11.3133.CrossRefPubMedPubMedCentral

31.

Gurba A, Taciak P, Sacharczuk M, Młynarczuk-Biały I, Bujalska-Zadrożny M, Fichna J. Gold (III) derivatives in colon cancer treatment. Int J Mol Sci. 2022;23(2):724. https://doi.org/10.3390/ijms23020724.CrossRefPubMedPubMedCentral

32.

Wang ZX, Zhang GQ, Li J, Ma HB, Zhou J, He E, Skog S. Elevated STK1p after the second-cycle-chemotherapy associated with failure poor survival in I-II Stage of NSCLCs- three cases reports. Clin Surg. 2021. https://doi.org/10.47829/COS.2021.61002.CrossRef

33.

Cigna Medical Coverage Policy, 2015. 1/15/2015, Coverage Policy Number 0171.

34.

Stewart BW, Bray F, Forman D, Ohgaki H, Straif K, Ullrich A, Wild CP. Cancer prevention as part of precision medicine: ‘plenty to be done.’ Carcinogenesis. 2016;37(1):2–9. https://doi.org/10.1093/carcin/bgv166.CrossRefPubMed

35.

Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, Esener S, Fitzgerald RC, Gambhir SS, Kuhn P, Rebbeck TR, Balasubramanian S. Early detection of cancer. Science. 2022;375(6586):9040. https://doi.org/10.1126/science.aay9040. (PMID:35298272).CrossRef

36.

Zhou J, Li H, Fang C, Jin C, Liu S, Zou R, Li J, Liu Y, He E, Skog S. Concentration of human thymidine kinase 1 discover invisible malignant human tumours. Eur J Cell Biol. 2022;101(4):151280. https://doi.org/10.1016/j.ejcb.2022.151280.CrossRefPubMed

37.

Margetis N, Kouloukoussa M, Pavlou K, Vrakas S, Mariolis-Sapsakos T. K-ras mutations as the earliest driving force in a subset of colorectal carcinomas. In Vivo. 2017;31(4):527–42. https://doi.org/10.21873/invivo.11091.CrossRefPubMedPubMedCentral

38.

Ferlitsch M, Moss A, Hassan C, Bhandari P, Dumonceau JM, Paspatis G, Jover R, Langner C, Bronzwaer M, Nalankilli K, Fockens P, Hazzan R, Gralnek IM, Gschwantler M, Waldmann E, Jeschek P, Penz D, Heresbach D, Moons L, Lemmers A, Paraskeva K, Pohl J, Ponchon T, Regula J, Repici A, Rutter MD, Burgess NG, Bourke MJ. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2017;49(3):270–97. https://doi.org/10.1055/s-0043-102569.CrossRefPubMed

39.

Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A. AJCC cancer staging manual. 7th ed. Berlin: Springer; 2010.

40.

Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704. https://doi.org/10.1056/NEJMoa043116.CrossRefPubMed

41.

Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25(1):102–9. https://doi.org/10.1200/JCO.2006.08.1075.CrossRefPubMed

42.

Gronowitz JS, Källander FR, Diderholm H, Hagberg H, Pettersson U. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer. 1984;33(1):5–12. https://doi.org/10.1002/ijc.2910330103.CrossRefPubMed

43.

Karlström AR, Neumüller M, Gronowitz JS, Källander CF. Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA. Mol Cell Biochem. 1990;92(1):23–35. https://doi.org/10.1007/BF00220716.CrossRefPubMed

44.

Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, National Academy of Clinical Biochemistry. Clin Chem. 2008;54(12):11–79. https://doi.org/10.1373/clinchem.2008.105601.CrossRef

45.

Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5 (PMID: 2183589).PubMed

Title: Is serum thymidine kinase 1 a prognostic biomarker in primary tumor location of colorectal carcinomas?
Authors: Yujing Fang
Sven Skog
Qingjian Ou
Zhiheng Chen
Senbo Liu
Ailian Hei
Jin Li
Ji Zhou
Ellen He
Desen Wan
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Rectal Cancer
Rectal Cancer
Colorectal Cancer
Colorectal Cancer
Biomarkers
Colon Cancer
Colon Cancer
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00614-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

TERT mutations-associated alterations in clinical characteristics, immune environment and therapy response in glioblastomas

Nonconvulsive status epilepticus characteristics in glioma patients: a retrospective study

Is it time for redefining oligometastatic disease? Analysis of lung metastases CT in ten tumor types

Resection margins, lymph node harvest and 3 year survival in open and laparoscopic colorectal cancer surgery; a prospective cohort study

Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition

Chemotherapy-induced thrombocytopenia: literature review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials